

Morten Madsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284953/publications.pdf>

Version: 2024-02-01

66
papers

2,561
citations

218381

26
h-index

197535

49
g-index

66
all docs

66
docs citations

66
times ranked

3017
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Diagnostic Performance of Inâ€Procedure Angiographyâ€Derived Quantitative Flow Reserve Compared to Pressureâ€Derived Fractional Flow Reserve: The FAVOR II Europeâ€Japan Study. Journal of the American Heart Association, 2018, 7, . | 1.6 | 240 |
| 2 | Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet, The, 2010, 375, 1090-1099. | 6.3 | 198 |
| 3 | SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ, The, 2021, 375, e068665. | 3.0 | 179 |
| 4 | Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet, The, 2013, 381, 661-669. | 6.3 | 173 |
| 5 | Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. Circulation, 2012, 125, 1246-1255. | 1.6 | 149 |
| 6 | Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology, 2010, 2, 137. | 1.5 | 147 |
| 7 | Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet, The, 2015, 385, 1527-1535. | 6.3 | 107 |
| 8 | Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, . | 1.4 | 104 |
| 9 | Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet, The, 2014, 383, 2047-2056. | 6.3 | 96 |
| 10 | The Western Denmark Heart Registry. Journal of the American College of Cardiology, 2018, 71, 1259-1272. | 1.2 | 90 |
| 11 | Risk Associated With Surgery WithinÂ12ÂMonths After Coronary Drug-Eluting StentÂImplantation. Journal of the American College of Cardiology, 2016, 68, 2622-2632. | 1.2 | 89 |
| 12 | Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER). American Heart Journal, 2018, 205, 97-109. | 1.2 | 61 |
| 13 | Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 109, 629-635. | 0.7 | 54 |
| 14 | Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. International Journal of COPD, 2016, 11, 455. | 0.9 | 53 |
| 15 | Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke, 2018, 49, 2568-2576. | 1.0 | 50 |
| 16 | Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial). American Journal of Cardiology, 2012, 110, 1585-1591. | 0.7 | 48 |
| 17 | 3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. JACC: Cardiovascular Interventions, 2012, 5, 812-818. | 1.1 | 43 |
| 18 | 2-Year Patient-Related Versus Stent-Related Outcomes. Journal of the American College of Cardiology, 2012, 60, 1140-1147. | 1.2 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. <i>EuroIntervention</i> , 2010, 5, 898-905. | 1.4 | 42 |
| 20 | Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark. <i>American Journal of Cardiology</i> , 2010, 105, 1513-1519. | 0.7 | 41 |
| 21 | Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy). <i>American Journal of Cardiology</i> , 2011, 108, 1232-1237. | 0.7 | 39 |
| 22 | Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 255-264. | 1.1 | 38 |
| 23 | Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. <i>Diabetes Care</i> , 2017, 40, 1103-1110. | 4.3 | 37 |
| 24 | Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354. | 1.0 | 32 |
| 25 | Evaluation of algorithms for registry-based detection of acute myocardial infarction following percutaneous coronary intervention. <i>Clinical Epidemiology</i> , 2016, Volume 8, 415-423. | 1.5 | 30 |
| 26 | Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 840-848. | 1.1 | 28 |
| 27 | Nonsteroidal Antiinflammatory Drug Use and Clinical Outcomes of Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 128-131. | 2.5 | 26 |
| 28 | Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 101-108. | 0.7 | 23 |
| 29 | Coronary artery disease and risk of adverse cardiac events and stroke. <i>European Journal of Clinical Investigation</i> , 2017, 47, 819-828. | 1.7 | 23 |
| 30 | Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. <i>Clinical Epidemiology</i> , 2013, 5, 357. | 1.5 | 21 |
| 31 | Comparison of Outcomes of Patients ≥ 80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , 2017, 70, 1395-1400. | 0.7 | 17 |
| 32 | The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. <i>EuroIntervention</i> , 2012, 8, 591-598. | 1.4 | 17 |
| 33 | Long-Term Outcome of Sirolimus-Eluting and Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (A Danish Organization for Randomized Trials on). <i>Journal of the American College of Cardiology</i> , 2017, 70, 1395-1400. | 0.7 | 17 |
| 34 | Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. <i>Thrombosis and Haemostasis</i> , 2016, 116, 172-180. | 1.8 | 15 |
| 35 | Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus. <i>Clinical Epidemiology</i> , 2019, Volume 11, 419-428. | 1.5 | 13 |
| 36 | Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial. <i>American Heart Journal</i> , 2018, 202, 49-53. | 1.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 22-27. | 1.8 | 12 |
| 38 | Invasively Measured Aortic Systolic Blood Pressure and Office Systolic Blood Pressure in Cardiovascular Risk Assessment. <i>Hypertension</i> , 2016, 68, 768-774. | 1.3 | 11 |
| 39 | Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1047-1054. | 1.7 | 10 |
| 40 | Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158. | 0.7 | 10 |
| 41 | Comorbidity and Quality of In-Hospital Care for Hip Fracture Patients. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 671-677.e4. | 1.2 | 9 |
| 42 | <p>Impact of the Charlson Comorbidity Index score on risk prediction by single-photon emission computed tomography myocardial perfusion imaging following myocardial infarction</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 901-910. | 1.5 | 8 |
| 43 | Association between anti-diabetes treatments and cardiovascular risk in diabetes patients with and without coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 351-359. | 0.9 | 8 |
| 44 | Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. <i>EuroIntervention</i> , 2014, 10, 212-223. | 1.4 | 8 |
| 45 | The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2921-e2929. | 1.8 | 8 |
| 46 | A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48. | 0.7 | 7 |
| 47 | Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 577-587. | 1.8 | 7 |
| 48 | Prediction Ability of Charlson, Elixhauser, and Rx-Risk Comorbidity Indices for Mortality in Patients with Hip Fracture. A Danish Population-Based Cohort Study from 2014 to 2018. <i>Clinical Epidemiology</i> , 2022, Volume 14, 275-287. | 1.5 | 7 |
| 49 | Impact of Co-morbidity on the Risk of First-Time Myocardial Infarction, Stroke, or Death After Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging. <i>American Journal of Cardiology</i> , 2014, 114, 510-515. | 0.7 | 6 |
| 50 | Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 23. | 2.7 | 6 |
| 51 | Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100301. | 3.0 | 6 |
| 52 | Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. <i>Endoscopy International Open</i> , 2016, 04, E527-E533. | 0.9 | 5 |
| 53 | Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 329-338. | 0.5 | 5 |
| 54 | Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 867-878. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Predicting stroke in patients without atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13103. | 1.7 | 5 |
| 56 | Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). <i>American Journal of Cardiology</i> , 2020, 125, 349-353. | 0.7 | 5 |
| 57 | Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart Registry. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094180. | 0.9 | 5 |
| 58 | Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , . | 0.4 | 5 |
| 59 | Coronary stent implantation and adverse cardiac events after surgery. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13030. | 1.7 | 3 |
| 60 | Risk of Myocardial Infarction in Patients Without Angiographic Coronary Artery Disease Compared With the General Population. <i>American Journal of Cardiology</i> , 2020, 132, 8-14. | 0.7 | 3 |
| 61 | Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 84. | 0.7 | 2 |
| 62 | Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 160, 14-20. | 0.7 | 2 |
| 63 | <p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus [Response to Letter]<p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 721-722. | 1.5 | 1 |
| 64 | Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). <i>BMC Cardiovascular Disorders</i> , 2012, 12, 18. | 0.7 | 0 |
| 65 | CHA 2 DS 2 â€œVASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, , e13717. | 1.7 | 0 |
| 66 | Patient-related healthcare disparities in the quality of acute hip fracture care: a 10-year nationwide population-based cohort study. <i>BMJ Open</i> , 2021, 11, e051424. | 0.8 | 0 |